A quiet analytical research laboratory at night, racks of glass vials along a dim bench.

Immune Resilience: Mechanisms, Status and Delivery

Immune actives range from nutrients with established roles (zinc, vitamin D) to peptides approved in some countries but not others (thymosin alpha-1) and research compounds with no approved use (LL-37). Most share a delivery problem: they are either degraded in the gut or poorly absorbed. Vegalab approaches the category as a stability and targeting problem, not a claim opportunity.

Innate and adaptive layers

Innate defenses include epithelial barriers, antimicrobial peptides such as the cathelicidin LL-37, and pattern recognition receptors that respond to microbial structures like beta-glucans. Adaptive immunity depends on T cell maturation in the thymus, which shrinks with age. A large share of the body's immune cells sit in gut-associated lymphoid tissue, so oral actives interact with immune signaling at the gut wall even when little reaches the blood. That interaction is real but hard to measure, which limits the evidence for many supplement claims.

Status of the main actives

Thymosin alpha-1 (thymalfasin) is approved in a number of countries outside the US and EU, mainly as an adjunct in hepatitis B, and holds orphan designations in the US; it is given by injection. LL-37 is a research compound with no approved human use. Yeast beta-glucans, zinc, vitamin C and vitamin D are supplement ingredients with jurisdiction-specific permitted claims (for example, EU authorized claims on normal immune function for certain vitamins and minerals).

Delivery constraints

Thymic peptides and LL-37 are cleaved by proteases and have short plasma half-lives. LL-37 is also cationic and binds to mucus and cell surfaces nonspecifically. Zinc salts are astringent and taste metallic in liquids. Particulate beta-glucans act at gut immune sites, so particle size and release location matter more than systemic absorption. Each problem points to a different encapsulation design, covered on the compound and challenge pages. Release location, not only dose, becomes the main design variable.

Key facts

Thymosin alpha-1 enhances T cell maturation and is used clinically in several countries for chronic hepatitis B and as a vaccine adjuvant (King and Tuthill 2016, Vitam Horm 102:151)
LL-37 is the only human cathelicidin and has direct antimicrobial and immunomodulatory activity (Vandamme et al. 2012, Cell Immunol 280:22)
EU authorized health claims include contribution of vitamin D and zinc to the normal function of the immune system (Regulation (EU) No 432/2012)

How our delivery technology applies

For peptides like thymosin alpha-1 and LL-37, a multi-layer shell can limit protease access and control release rate, which matters for any route beyond injection. For particulate actives such as beta-glucans, encapsulation lets a formulator set particle size and release location in the gut. For zinc, an outer biopolymer layer reduces taste and mucosal irritation. These are formulation variables; clinical effect depends on the active.

Scope an immune-category formulation with Vegalab's development team.